We observed that bortezomib given at our tested therapeutic dose (1 mg/kg body weight) had no significant effects either on total leukocyte counts in control or tumor-draining LN, tumor-infiltrating lymphocytes, and spleen, or in subsets of CD4+T, CD8+T, and CD11c+ cells [33]. The gene discussed is ITGAX; the disease is neoplasm.